ZBH Zimmer Biomet Holdings, Inc. Common Stock

NYSE · US · Healthcare · Medical Devices · zimmerbiomet.com

88.29USD+0.26%Mkt Cap: 16.84B $P/E: 21.434d ago

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip pr…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.60BUSDP/E 18.7

STE

STERIS plc (Ireland) Ordinary Shares

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap16.84B USD

Enterprise Value23.99B USD

Revenue (TTM)8.51B USD

Gross Profit5.74B USD

Net Income (TTM)705.10M USD

Revenue/Share43.50 USD

Last Price88.29 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees17.0K

CountryUS

SectorHealthcare

IndustryMedical Devices

ISIN—

Valuation

P/E (Trailing)21.43

P/E (Forward)9.74

PEG0.55

EV/EBITDA9.50

EV/Revenue2.82

P/S1.98

P/B1.33

EPS (TTM)4.12

EPS (Forward)9.07

52W Range

79.1233% of range106.88

52W High106.88 USD

52W Low79.12 USD

Profitability

Gross Margin69.71%

Oper. Margin17.96%

EBITDA Margin29.67%

Profit Margin8.57%

ROE5.55%

ROA3.05%

Growth

Revenue Growth4.80%

Earnings Growth33.80%

Cash Flow & Leverage

Operating CF1.70B USD

CapEx (TTM)276.90M USD

FCF Margin12.60%

FCF Yield6.37%

Net Debt7.14B USD

Net Debt/EBITDA2.83

Balance Sheet

Debt/Equity0.59

Current Ratio1.69

Quick Ratio0.74

Book Value/Sh66.23 USD

Cash/Share2.44 USD

Dividends

Fwd Div Rate0.96 USD

Trail. Div Rate0.96 USD

Div. Yield1.09%

5Y Avg Yield0.86%

Payout Ratio23.30%

Ex-Div DateSep 30, 2026

Pay DateOct 30, 2026

Splits

Last Split103:100

Split DateMar 1, 2022

Analyst Consensus

Rating2.4 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)107.57 USD

Upside (mean)+21.8%

Target Range93.00 USD – 130.00 USD

93.00+21.8% to mean130.00

# Analysts21

Ownership

Shares Out.190.74M

Float190.13M

Insiders0.16%

Institutions111.35%

Short Interest

Short Ratio5.2d

Short % Float5.93%

Short % Out.4.50%

Shares Short8.58M

Short (prev mo.)8.80M

Technical

SMA 5096.08 (-8.1%)

SMA 20091.34 (-3.3%)

Beta0.47

S&P 52W Chg14.58%

Avg Vol (30d)1.85M

Avg Vol (10d)2.07M

Technical Indicators

RSI (14)35.0

MACD-2.1030

MACD Signal-1.4656

MACD Hist.-0.6374

BB Upper99.33 USD

BB Middle93.11 USD

BB Lower86.89 USD

BB Width13.37%

ATR (14)2.521 USD

Vol Ratio (20d)0.92x